You are here: Home » Markets » News
Business Standard

Alembic Pharma zooms 20% as USFDA gives nod for anti-depression drug

The stock is locked in upper circuit of 20% at Rs 522 after the company received approval from the USFDA for its ANDA Bupropion hydrochloride tablets USP, 75 mg and 100 mg.

SI Reporter  |  Mumbai 

pharma
According to UNAIDS, India has 2.1 million people living with HIV

Shares of are locked in upper circuit of 20% at Rs 522 per share on the after the company said that it has received approval from the US drug health regulator for drug.

“The company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) tablets USP, 75 mg and 100 mg,” Alembic Pharma said in a press release.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Wellbutrin tablets, 75 mg and 100 mg, of GlaxoSmithKline LLC. tablets are indicated for the treatment of major depressive disorder.

According to IMS, tablets USP, 75 mg and 100 mg, have an estimated market size of US$ 37 million for twelve months ending December 2017.

Alembic Pharma said it has now a total of 72 ANDA approvals (64 final approvals and 8 tentative approvals) from

Till 01:00 PM; a combined 536,880 equity shares changed hands and there were pending buy orders for 44,446 shares on the and


First Published: Mon, June 11 2018. 13:11 IST
RECOMMENDED FOR YOU